Technavio estimates the global bile duct cancer market to grow by USD 105.55 million from 2021 to 2026, progressing at a CAGR of 7.79% during the forecast period. The report analyzes the market across type (extrahepatic bile duct cancer and intrahepatic bile duct cancer) and geography (North America, Europe, Asia, and ROW).
Discover growth opportunities across each segment and make informed decisions by purchasing our full report.
Download a Free Sample Before Purchasing
The bile duct cancer market report offers a comprehensive analysis of the strategies adopted by vendors and the trends, drivers, and challenges affecting the market size.
The market is driven by the growing preference for chemotherapy drugs in developing countries. The preference for chemotherapy has been declining in developed countries. However, this practice has remained strong in developing regions. For instance, in India, a majority of physicians and approximately 30-30% of cancer patients still prefer chemotherapy for the treatment of cancer. This is continuously creating growth opportunities for chemotherapy drug manufacturers, which is driving the growth of the market.
In addition, the increasing incidence of bile duct cancer and new drug approvals will further accelerate the growth of the market. However, the lack of adequate healthcare infrastructure in developing nations will reduce the growth potential in the market.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
Companies Mentioned
AstraZeneca Plc: The company offers bile duct cancer treatment through its Imfinzi plus chemotherapy.
BridgeBio Pharma Inc.: The company offers bile duct cancer treatment through its subisidiary, QED Therapeutics Inc.
Bristol-Myers Squibb Co.: The company offers bile duct cancer treatment under the brand name OPDIVO.
Hutchison China Meditech Ltd.: The company offers bile duct cancer treatment through its drug named HMPL 453.
Incyte Corp.: The company offers FDA approved prescription medicine named PEMAZYRE to treat adults with bile duct cancer.
Subscribe to our "Lite Plan" billed annually at USD 3000 to join a community, who are eligible to view 3 reports monthly and download 3 reports annually.
Related Reports:
Lung Cancer Therapeutics Market by Type and Geography - Forecast and Analysis 2021-2025
Chemotherapy-induced Nausea and Vomiting Drugs Market by Therapy and Geography - Forecast and Analysis 2021-2025
Bile Duct Cancer Market Scope |
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 7.79% |
Market growth 2022-2026 |
USD 105.55 million |
Market structure |
Fragmented |
YoY growth (%) |
7.10 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 41% |
Key consumer countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
AstraZeneca Plc, BridgeBio Pharma Inc., Bristol-Myers Squibb Co., Hutchison China Meditech Ltd., Incyte Corp., J-Pharma Co. Ltd., Merck KGaA, RemeGen Co. Ltd, Servier, and Sino Biopharmaceutical Ltd. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article